Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Erlotinib monotherapy for the maintenance treatment of advanced or metastatic non-small cell lung cancer and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 24 March 2011.
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): final appraisal determination
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to consultee, commentator and public comments on the ACD and comments from website consultation
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): response to comments on the second Appraisal Consultation document (ACD2) from Liverpool Reviews and Implementation Group
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): consultee and commentator comments on the ACD
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): comments on the ACD2 through web consultation
This page was last updated: 08 March 2011